These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 23968379)

  • 1. Emerging drugs for polycythemia vera.
    Tibes R; Mesa RA
    Expert Opin Emerg Drugs; 2013 Sep; 18(3):393-404. PubMed ID: 23968379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?
    Nazha A; Gerds AT
    Oncologist; 2016 Apr; 21(4):475-80. PubMed ID: 26975864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera.
    Reiter A; Harrison C
    Curr Hematol Malig Rep; 2016 Oct; 11(5):356-67. PubMed ID: 26894383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Therapeutic Approaches in Polycythemia Vera.
    Falchi L; Newberry KJ; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl(0):S27-33. PubMed ID: 26297275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure?
    Nazha A; Khoury JD; Verstovsek S; Daver N
    Crit Rev Oncol Hematol; 2016 Sep; 105():112-7. PubMed ID: 27401783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diagnosis and therapy of polycythemia vera in the era of JAK2].
    Lengfelder E
    Dtsch Med Wochenschr; 2013 Feb; 138(7):331-6. PubMed ID: 23393003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A
    Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group.
    Sirhan S; Busque L; Foltz L; Grewal K; Hamm C; Laferriere N; Laneuville P; Leber B; Liew E; Olney HJ; Prchal J; Porwit A; Gupta V
    Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):715-27. PubMed ID: 26433906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polycythemia vera: current pharmacotherapy and future directions.
    Hensley B; Geyer H; Mesa R
    Expert Opin Pharmacother; 2013 Apr; 14(5):609-17. PubMed ID: 23480062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can pegylated interferon improve the outcome of polycythemia vera patients?
    Crisà E; Cerrano M; Beggiato E; Benevolo G; Lanzarone G; Manzini PM; Borchiellini A; Riera L; Boccadoro M; Ferrero D
    J Hematol Oncol; 2017 Jan; 10(1):15. PubMed ID: 28086927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and future treatment options for polycythemia vera.
    Griesshammer M; Gisslinger H; Mesa R
    Ann Hematol; 2015 Jun; 94(6):901-10. PubMed ID: 25832853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polycythemia vera: aspects of its current diagnosis and initial treatment.
    Silver RT; Abu-Zeinah G
    Expert Rev Hematol; 2023 Apr; 16(4):253-266. PubMed ID: 37013802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG.
    Michiels JJ; Barbui T; Finazzi G; Fuchtman SM; Kutti J; Rain JD; Silver RT; Tefferi A; Thiele J
    Leuk Lymphoma; 2000 Jan; 36(3-4):239-53. PubMed ID: 10674896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
    Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Recent advances in polycythemia vera treatment].
    Edahiro Y
    Rinsho Ketsueki; 2020; 61(9):1187-1194. PubMed ID: 33162515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?
    Vannucchi AM; Guglielmelli P
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):480-488. PubMed ID: 29222296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anagrelide hydrochloride and ruxolitinib for treatment of polycythemia vera.
    Kremyanskaya M; Mascarenhas J; Hoffman R
    Expert Opin Pharmacother; 2015 Jun; 16(8):1185-94. PubMed ID: 25873215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia.
    Finazzi G; Barbui T
    Leukemia; 2008 Aug; 22(8):1494-502. PubMed ID: 18596737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.